← All Xilio Therapeutics, INC filings

Xilio Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
XLO
Xilio Therapeutics, INC
10-K: Xilio Therapeutics Reports Reduced Losses, Strategic Progress in 2025
Xilio Therapeutics, a clinical-stage biotechnology company, reported a significant reduction in net losses for 2025, driven by increased collaboration revenue and strategic advancements in its immuno-oncology pipeline.
NASDAQ
XLO
Xilio Therapeutics, INC
10-K: Xilio Therapeutics Reports 2024 Results, Highlights Progress in Tumor-Activated Immunotherapy Pipeline
Xilio Therapeutics files its 2024 10-K, detailing clinical progress and strategic collaborations in its tumor-activated immuno-oncology pipeline.
NASDAQ
XLO
Xilio Therapeutics, INC
10-K: Xilio Therapeutics Reports Full Year 2023 Results, Announces Strategic Reprioritization and Gilead Partnership
Xilio Therapeutics reports its 2023 financial results, strategic portfolio reprioritization, workforce reduction, and an exclusive licensing agreement with Gilead for its IL-12 program.